World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
44740
World Ranking
14359
National Ranking
7260

Bernard Levin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Bernard Levin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 335 publications — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Bernard Levin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Bernard Levin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 85 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Bernard Levin is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a significant focus on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, and Organic Chemistry.

The scientist's work covers key topics such as Cancer-related Molecular Pathways, Advanced Breast Cancer Therapies, Lung Cancer Research Studies, Protein Degradation and Inhibitors, Ubiquitin and Proteasome Pathways, Colorectal Cancer Screening and Detection, and Gastric Cancer Management and Outcomes.

Bernard Levin has published research in a variety of well-known venues, including:

  • Cancer Research (2 publications)
  • Molecular Cancer Therapeutics (2 publications)
  • Gut (1 publication)
  • bioRxiv (Cold Spring Harbor Laboratory) (1 publication)
  • Nature (1 publication)

Frequent coauthors collaborating with Bernard Levin include:

  • David J. Earp (8 joint publications)
  • Catherine E. Gleason (7 joint publications)
  • James B. Aggen (7 joint publications)
  • Lifen Liu (7 joint publications)
  • Pablo D. García (7 joint publications)

Notable recent papers authored or coauthored by Bernard Levin are:

  • An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles, 2023, Gut
  • Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity, 2024, bioRxiv (Cold Spring Harbor Laboratory)
  • Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors, 2025, Nature
  • Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity, 2025, Journal of Medicinal Chemistry
  • Abstract 5379: Macrocycles inhibiting RxL-mediated binding of substrates to Cyclin A are synthetic lethal in Rb mutated small cell lung carcinoma (SCLC), 2022, Cancer Research

Best Publications

  • Guidelines for colonoscopy surveillance after polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society

    Sidney J. Winawer;Ann G. Zauber;Robert H. Fletcher;Jonathon S. Stillman

  • Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.

    Bernard Levin;David A Lieberman;Beth McFarland;Kimberly S Andrews

  • The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis

    Gideon Steinbach;Patrick M. Lynch;Robin K S Phillips;Marina H. Wallace

  • Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi‐Society Task Force on Colorectal Cancer, and the American College of Radiology*†

    Bernard Levin;David A. Lieberman;Beth McFarland;Robert A. Smith

  • American Cancer Society guidelines for the early detection of cancer.

    Robert A. Smith;Curtis J. Mettlin;Kourtney Johnston Davis;Harmon Eyre

  • Celecoxib for the Prevention of Colorectal Adenomatous Polyps

    Nadir Arber;Craig J. Eagle;Julius Spicak;István Rácz

  • American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers: ALSO: Update 2001—Testing for Early Lung Cancer Detection

    Robert A. Smith;Andrew C. von Eschenbach;Richard Wender;Bernard Levin

  • Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors.

    David Sidransky;Takashi Tokino;Stanley R. Hamilton;Kenneth W. Kinzler

  • Meta-analyses of Colorectal Cancer Risk Factors

    Constance M. Johnson;Caimiao Wei;Joe E. Ensor;Derek J. Smolenski

  • Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.

    Douglas B. Evans;Tyvin A. Rich;David R. Byrd;Karen R. Cleary

  • Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy.

    M O Blackstone;R H Riddell;B H Rogers;B Levin

  • American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: Update 1997

    Tim Byers;Bernard Levin;David Rothenberger;Gerald D. Dodd

  • National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002.

    Patrick Dl;Ferketich Sl;Frame Ps;Harris Jj

  • Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer.

    Douglas K. Rex;Charles J. Kahi;Bernard Levin;Robert A. Smith

  • A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.

    R.K.S. Phillips;Marina Wallace;P.M. Lynch;E. Hawk

  • Detecting Colorectal Cancer in Stool With the Use of Multiple Genetic Targets

    Seung Myung Dong;Giovanni Traverso;Constance M Johnson;Li Geng

  • Detection of APC mutations in fecal DNA from patients with colorectal tumors.

    Giovanni Traverso;Anthony Shuber;Bernard Levin;Constance Johnson

  • Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis

    Scott D. Solomon;Janet Wittes;Peter V. Finn;Robert Fowler

  • The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma A Prospective Randomized Phase III Trial

    Nicholas Petrelli;Harold O. Douglass;Lemuel Herrera;David Russell

  • National Institutes of Health State-of-the-Science Conference Statement: Symptom Management in Cancer: Pain, Depression, and Fatigue, July 15-17, 2002.

    Donald L. Patrick;Jürgen Unützer

Frequent Co-Authors

Jaffer A. Ajani
Jaffer A. Ajani The University of Texas MD Anderson Cancer Center
James L. Abbruzzese
James L. Abbruzzese Duke University
Robert A. Smith
Robert A. Smith University of Birmingham
Sidney J. Winawer
Sidney J. Winawer Memorial Sloan Kettering Cancer Center
Graeme P. Young
Graeme P. Young Flinders University
John H. Bond
John H. Bond Veterans Health Administration
Douglas K. Rex
Douglas K. Rex Indiana University
Patrick M. Lynch
Patrick M. Lynch The University of Texas MD Anderson Cancer Center
Melissa L. Bondy
Melissa L. Bondy Stanford University
Christopher I. Amos
Christopher I. Amos Baylor College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond traditional medical school, numerous online degree options offer flexible pathways. Healthcare administration is a crucial field, combining leadership and organizational skills with a passion for improving patient outcomes. Students can consider earning a bachelors in health administration, which opens doors to entry-level management roles in hospitals, clinics, and public health organizations.

Professionals seeking to advance their careers may look at the cost benefits of a masters in healthcare administration cost-effective program. These programs are designed for working adults and frequently offered online, helping you gain managerial expertise without stepping away from your current role.

Nursing professionals aiming for leadership or advanced practice roles can find the cheapest dnp program options online, making a Doctor of Nursing Practice degree more accessible than ever.

Additionally, if you’re interested in pharmacy, there are flexible, accredited distance-learning opportunities. Discover a pharmacy school online accredited program, which prepares you for a dynamic and vital role in medication therapy management.

Best Scientists Citing Bernard Levin

Trending Scientists

Recently Published Articles